Crescent Grove Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $991K | Buy |
8,184
+4
| +0% | +$462 | 0.1% | 136 |
|
|
2025
Q4 | $868K | Sell |
8,180
-1,276
| -13% | -$120K | 0.08% | 136 |
|
|
2025
Q3 | $800K | Buy |
9,456
+1,155
| +14% | +$95.1K | 0.08% | 137 |
|
|
2025
Q2 | $664K | Buy |
8,301
+35
| +0.4% | +$2.78K | 0.06% | 146 |
|
|
2025
Q1 | $749K | Sell |
8,266
-557
| -6% | -$52K | 0.08% | 127 |
|
|
2024
Q4 | $884K | Buy |
8,823
+508
| +6% | +$52.4K | 0.09% | 118 |
|
|
2024
Q3 | $951K | Sell |
8,315
-479
| -5% | -$56.9K | 0.1% | 118 |
|
|
2024
Q2 | $1.1M | Sell |
8,794
-6,113
| -41% | -$787K | 0.12% | 107 |
|
|
2024
Q1 | $1.97M | Buy |
14,907
+3
| +0% | +$370 | 0.21% | 74 |
|
|
2023
Q4 | $1.64M | Buy |
14,904
+2
| +0% | +$208 | 0.18% | 80 |
|
|
2023
Q3 | $1.54M | Buy |
14,902
+121
| +0.8% | +$13K | 0.19% | 79 |
|
|
2023
Q2 | $1.72M | Sell |
14,781
-2,272
| -13% | -$258K | 0.18% | 74 |
|
|
2023
Q1 | $1.83M | Sell |
17,053
-2,443
| -13% | -$264K | 0.21% | 66 |
|
|
2022
Q4 | $2.18M | Sell |
19,496
-131
| -0.7% | -$13.4K | 0.23% | 67 |
|
|
2022
Q3 | $1.7M | Buy |
19,627
+1,708
| +10% | +$152K | 0.2% | 63 |
|
|
2022
Q2 | $1.65M | Sell |
17,919
-2,217
| -11% | -$197K | 0.17% | 65 |
|
|
2022
Q1 | $1.67M | Buy |
20,136
+2,927
| +17% | +$231K | 0.16% | 70 |
|
|
2021
Q4 | $1.33M | Buy |
17,209
+442
| +3% | +$35.2K | 0.12% | 91 |
|
|
2021
Q3 | $1.27M | Buy |
16,767
+49
| +0.3% | +$3.73K | 0.13% | 89 |
|
|
2021
Q2 | $1.31M | Buy |
16,718
+759
| +5% | +$56.5K | 0.14% | 86 |
|
|
2021
Q1 | $1.18M | Buy |
15,959
+1,059
| +7% | +$78.1K | 0.14% | 82 |
|
|
2020
Q4 | $1.17M | Buy |
14,900
+300
| +2% | +$22.9K | 0.15% | 71 |
|
|
2020
Q3 | $1.16M | Buy |
14,600
+3
| +0% | +$235 | 0.23% | 52 |
|
|
2020
Q2 | $1.09M | Buy |
14,597
+36
| +0.2% | +$2.71K | 0.23% | 53 |
|
|
2020
Q1 | $1.08M | Sell |
14,561
-66
| -0.5% | -$5.19K | 0.24% | 51 |
|
|
2019
Q4 | $1.28M | Buy |
14,627
+3
| +0% | +$246 | 0.22% | 59 |
|
|
2019
Q3 | $1.18M | Sell |
14,624
-114
| -0.8% | -$9.14K | 0.23% | 57 |
|
|
2019
Q2 | $1.19M | Buy |
14,738
+328
| +2% | +$25.1K | 0.22% | 55 |
|
|
2019
Q1 | $1.15M | Buy |
14,410
+71
| +0.5% | +$5.31K | 0.24% | 50 |
|
|
2018
Q4 | $1.05M | Buy |
14,339
+81
| +0.6% | +$5.72K | 0.22% | 55 |
|
|
2018
Q3 | $972K | Buy |
14,258
+3
| +0% | +$191 | 0.21% | 58 |
|
|
2018
Q2 | $832K | Buy |
14,255
+3
| +0% | +$169 | 0.21% | 61 |
|
|
2018
Q1 | $747K | Buy |
14,252
+565
| +4% | +$30.5K | 0.18% | 62 |
|
|
2017
Q4 | $741K | Sell |
13,687
-130
| -0.9% | -$7.21K | 0.19% | 65 |
|
|
2017
Q3 | $850K | Sell |
13,817
-3,904
| -22% | -$237K | 0.22% | 58 |
|
|
2017
Q2 | $1.09M | Buy |
+17,721
| New | +$1.08M | 0.31% | 46 |
|
Other funds holding MRK
VCM
VPM
Crescent Grove Advisors's MRK Position: Q1 2026 in Review
Crescent Grove Advisors increased its Merck (MRK) stake by 0.05% in Q1 2026, buying an estimated $462 and bringing the position to 8,184 shares worth $991K. The position accounts for 0.1% of the portfolio, ranked #136.
Crescent Grove Advisors first reported a position in MRK in Q2 2017 and has held it in 36 quarters since. The position peaked at $2.18M in Q4 2022. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Crescent Grove Advisors held 8,184 shares of Merck worth $991K as of Q1 2026.
- Crescent Grove Advisors bought 4 Merck shares in Q1 2026, an estimated $462.
- Merck made up 0.1% of Crescent Grove Advisors's portfolio in Q1 2026, its #136 holding.
- Crescent Grove Advisors first reported a position in Merck in Q2 2017 and has held it in 36 quarters since.
- Crescent Grove Advisors's Merck position peaked at $2.18M in Q4 2022.
- 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.